Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glutamate signalling in bone.

T M Skerry1, A F Taylor

  • 1Department of Biology, The University of York, PO Box No 373, York, Y01 5YW, UK. tms3@york.ac.uk

Current Pharmaceutical Design
|May 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compound heterozygous variants in NBAS as a cause of atypical osteogenesis imperfecta.

Bone·2016
Same author

Helical Turing patterns in the Lengyel-Epstein model in thin cylindrical layers.

Chaos (Woodbury, N.Y.)·2015
Same author

A bistable switch in pH in urease-loaded alginate beads.

Chemical communications (Cambridge, England)·2014
Same author

Complex organizing centers in groups of oscillatory particles.

Physical chemistry chemical physics : PCCP·2011
Same author

Relative efficiency of chlamydia screening in non-clinical settings in two California counties.

International journal of STD & AIDS·2009
Same author

The role of glutamate in the regulation of bone mass and architecture.

Journal of musculoskeletal & neuronal interactions·2008
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Glutamate, known for brain signaling, also plays a key role in bone. Targeting glutamate pathways offers new therapeutic strategies for bone diseases.

Area of Science:

  • Bone biology
  • Neuroscience
  • Pharmacology

Background:

  • Glutamate is a well-established neurotransmitter in the central nervous system.
  • Emerging evidence suggests glutamate also functions as a signaling molecule in bone tissue.
  • Understanding non-neuronal roles of signaling molecules can accelerate therapeutic development.

Purpose of the Study:

  • To review the discovery and evidence for glutamate's role in bone signaling.
  • To identify current research gaps and future directions in this field.
  • To highlight the potential of existing research for bone disease therapies.

Main Methods:

  • Literature review of studies on glutamate signaling in bone.
  • Analysis of research connecting synaptic and skeletal functions of glutamate.

Related Experiment Videos

  • Examination of therapeutic targets related to glutamate pathways.

    • Main Results:

    • Glutamate signaling in bone shares similarities with its established role in synaptic neurotransmission.
    • Modulators of glutamate release, uptake, and receptor function are potential therapeutic agents for skeletal pathophysiology.
    • Existing studies may contain valuable data on glutamate's non-neuronal functions.

    Conclusions:

    • Glutamate is a significant signaling molecule in bone, offering novel therapeutic targets.
    • Further research is needed to resolve current uncertainties and advance skeletal treatments.
    • Repurposing existing knowledge of glutamate modulators can expedite the development of bone disease therapies.